Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

Rhea-AI Summary

Paragon 28 (NYSE: FNA), a leading medical device company focused on the foot and ankle orthopedic market, has announced it will report its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time on the same day to discuss the results.

Investors can participate in the conference call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. The webcast will be available on the 'Investors' section of Paragon 28's website at ir.paragon28.com and will be archived for replay for at least 90 days after the event.

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.

Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the “Investors” section of the Company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241017202625/en/

Investor Contact:

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (720) 912-1332

mbrinckman@paragon28.com

Source: Paragon 28, Inc.

FAQ

When will Paragon 28 (FNA) report its Q3 2024 financial results?

Paragon 28 (FNA) will report its third quarter 2024 financial results after market close on Tuesday, November 12, 2024.

How can investors listen to Paragon 28's (FNA) Q3 2024 earnings call?

Investors can listen to Paragon 28's (FNA) Q3 2024 earnings call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. The call begins at 4:30 p.m. Eastern Time on November 12, 2024.

Where can I find the webcast for Paragon 28's (FNA) Q3 2024 earnings call?

The webcast for Paragon 28's (FNA) Q3 2024 earnings call will be available on the 'Investors' section of the company's website at ir.paragon28.com. It will be archived for replay for at least 90 days after the event.

What is Paragon 28's (FNA) stock symbol and primary business focus?

Paragon 28's stock symbol is FNA, and it is listed on the NYSE. The company is a leading medical device company exclusively focused on the foot and ankle orthopedic market.